{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:37:55Z","timestamp":1782981475689,"version":"3.54.5"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016423","name":"Cook Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.03.022","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:44:55Z","timestamp":1775753095000},"page":"407-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["An update on cystic fibrosis Hepato-biliary involvement"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-3390","authenticated-orcid":false,"given":"A. Jay","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.J.A.","family":"Bodewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.03.022_bib0001","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0002","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0003","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0004","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","article-title":"Towards a standardized classification of the Hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN position paper","volume":"78","author":"Bodewes","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0006","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","author":"Sellers","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0007","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","article-title":"Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen","volume":"16","author":"Woodruff","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MPG.0000000000002413","article-title":"Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of Liver disease","volume":"69","author":"Ling","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiology.211.1.r99ap13229","article-title":"Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients","volume":"211","author":"Patriquin","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jcf.2019.09.016","article-title":"Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study","volume":"19","author":"Cipolli","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MPG.0000000000000758","article-title":"Increase of serum gamma-glutamyltransferase associated with development of cirrhotic cystic fibrosis liver disease","volume":"61","author":"Bodewes","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0012","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0013","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcf.2026.03.022_bib0014","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2026.03.022_bib0015","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.03.022_bib0016","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.28016","article-title":"Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease","volume":"62","author":"Leung","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0017","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.cgh.2019.03.015","article-title":"Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0018","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","article-title":"A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease","volume":"19","author":"Karnsakul","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14155404","article-title":"Evaluating the diagnostic potential of the FIB-4 index for cystic fibrosis-associated liver disease in adults: a comparison with transient elastography","volume":"14","author":"Armstrong","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2026.03.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.03.022_bib0021","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jcf.2025.05.003","article-title":"Evolution of hepatobiliary involvement in cystic fibrosis children on CFTR modulators","volume":"24","author":"Auvray","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0022","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.03.022_bib0023","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"Boelle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212779","article-title":"The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study","volume":"14","author":"Toledano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.03.022_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2022.05.033","article-title":"Porto-sinusoidal vascular disorder","volume":"77","author":"De Gottardi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0026","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","article-title":"Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension","volume":"17","author":"Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0027","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11845-022-03153-0","article-title":"Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis","volume":"192","author":"JP","year":"2023","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jcf.2026.03.022_bib0028","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/liv.15748","article-title":"The non-invasive evaluation of liver involvement in patients with cystic fibrosis: a prospective study","volume":"43","author":"Dajti","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jcf.2026.03.022_bib0029","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcf.2023.07.002","article-title":"Cystic fibrosis registry of I, et al. The natural history of cystic fibrosis liver disease a prospective cohort study","volume":"22","author":"Rowland","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis","volume":"66","author":"Ye","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0031","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jhep.2011.03.028","article-title":"Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation","volume":"55","author":"Chryssostalis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0032","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jcf.2018.11.009","article-title":"Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands","volume":"18","author":"Pals","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0033","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.chest.2015.10.040","article-title":"Hepatopulmonary syndrome in patients with cystic fibrosis and liver disease","volume":"149","author":"Breuer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2026.03.022_bib0034","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1002\/cphy.c210009","article-title":"Hepatopulmonary syndrome and portopulmonary hypertension: pulmonary vascular complications of liver disease","volume":"11","author":"Del Valle","year":"2021","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0035","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/adc.66.6.698","article-title":"Prevalence of liver disease in cystic fibrosis","volume":"66","author":"Scott-Jupp","year":"1991","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2026.03.022_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/crad.2001.0861","article-title":"Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review","volume":"57","author":"Williams","year":"2002","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0037","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcf.2017.07.006","article-title":"Gallbladder and bile duct disease in cystic fibrosis","volume":"16","author":"Assis","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0038","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2009.05.002","article-title":"Hepatocellular carcinoma complicating cystic fibrosis related liver disease","volume":"8","author":"O'Donnell","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0039","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00042737-200510000-00018","article-title":"Advanced hepatocellular carcinoma associated with cystic fibrosis","volume":"17","author":"Kelleher","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12890-020-01337-x","article-title":"Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report","volume":"20","author":"Carson","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2026.03.022_bib0041","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djs481","article-title":"Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States","volume":"105","author":"Maisonneuve","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcf.2026.03.022_bib0042","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hep.510270126","article-title":"A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease","volume":"27","author":"Lindblad","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0043","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jcf.2016.07.009","article-title":"Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients","volume":"15","author":"van der Feen","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0044","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2026.03.022_bib0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2021.03.014","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study","volume":"21","author":"Colombo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0046","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jcf.2026.03.022_bib0047","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","article-title":"Cystic fibrosis-related cirrhosis","volume":"16","author":"Leung","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0048","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in cystic fibrosis-related diabetes epidemiology between 2003 and 2018 from the U.S. Cystic fibrosis foundation patient registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2026.03.022_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251328210","article-title":"Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment","volume":"16","author":"Cobb","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jcf.2026.03.022_bib0050","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(75)90121-X","article-title":"Defective essential-fatty-acid metabolism in cystic fibrosis","volume":"2","author":"Rivers","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.03.022_bib0051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115528","article-title":"Omega-3 lipid mediators: modulation of the M1\/M2 macrophage phenotype and its protective role in chronic liver diseases","volume":"24","author":"Videla","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.03.022_bib0052","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000114208","article-title":"Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients","volume":"51","author":"Van Biervliet","year":"2007","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jcf.2026.03.022_bib0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000477913","article-title":"Serum phospholipid fatty acid composition in cystic fibrosis patients with and without liver cirrhosis","volume":"71","author":"Drzymala-Czyz","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jcf.2026.03.022_bib0054","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Cystic fibrosis agents. In. LiverTox.com: National Institute of Diabetes and Digestive and Kidney Diseases.; 2025."},{"key":"10.1016\/j.jcf.2026.03.022_bib0055","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with Cystic fibrosis exposed to Elexacaftor\/Tezacaftor\/Ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jcf.2026.03.022_bib0056","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcf.2021.07.014","article-title":"The impact of liver disease on mortality in cystic fibrosis-A systematic review","volume":"21","author":"Sasame","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0057","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0058","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17476348.2024.2365842","article-title":"Management of liver disease and portal hypertension in cystic fibrosis: a review","volume":"18","author":"Colombo","year":"2024","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2026.03.022_bib0059","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1399-3046.2012.01652.x","article-title":"Portal hypertension in children: expert pediatric opinion on the report of the Baveno v consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"16","author":"Shneider","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcf.2026.03.022_bib0061","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jcf.2020.06.019","article-title":"Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient","volume":"19","author":"Lupi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0062","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4274\/dir.2022.221818","article-title":"Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results","volume":"30","author":"Hermie","year":"2024","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0063","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MCG.0000000000001180","article-title":"Role of interventional radiology in complications of portal hypertension","volume":"53","author":"Shreve","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0064","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-8278(99)80166-4","article-title":"Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension","volume":"31","author":"Debray","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0065","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jpedsurg.2019.01.035","article-title":"Cystic fibrosis and portal hypertension: distal splenorenal shunt can prevent the need for future liver transplant","volume":"54","author":"Lemoine","year":"2019","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.jcf.2026.03.022_bib0066","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.cgh.2023.03.019","article-title":"Update in the treatment of the complications of cirrhosis","volume":"21","author":"Abraldes","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0067","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ppul.20713","article-title":"Partial splenectomy for portal hypertension in cystic fibrosis related liver disease","volume":"42","author":"Louis","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0068","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/adc.2006.093773","article-title":"Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series","volume":"91","author":"Linnane","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2026.03.022_bib0069","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jpedsurg.2006.05.006","article-title":"Outcome of total splenectomy with portosystemic shunt for massive splenomegaly and variceal bleeding in cystic fibrosis","volume":"41","author":"Robberecht","year":"2006","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.jcf.2026.03.022_bib0070","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lt.25421","article-title":"A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis-associated liver disease","volume":"25","author":"Freeman","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jcf.2026.03.022_bib0071","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic fibrosis foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0072","first-page":"301","article-title":"Cystic fibrosis with liver involvement in adults has a benign course. Results from a tertiary referral center cohort","volume":"115","author":"Marinero Martinez-Lazaro","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jcf.2026.03.022_bib0073","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajt.16791","article-title":"Liver transplant in children and adults with cystic fibrosis: impact of growth failure and nutritional status","volume":"22","author":"Cheng","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcf.2026.03.022_bib0074","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.33.3.387","article-title":"Biliary complications of cystic fibrosis","volume":"33","author":"O'Brien","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.jcf.2026.03.022_bib0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.21405","article-title":"Sclerosing cholangitis: a focus on secondary causes","volume":"44","author":"Abdalian","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0076","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0168-8278(99)80259-1","article-title":"Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study","volume":"30","author":"Durieu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0077","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s10620-006-9259-1","article-title":"Hepatolithiasis and cholangiocarcinoma in cystic fibrosis: a case series and review of the literature","volume":"52","author":"Perdue","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcf.2026.03.022_bib0078","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/MEG.0b013e3282f4de7e","article-title":"Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis","volume":"20","author":"Naderi","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0079","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/qjmed\/hcz150","article-title":"Hepatocellular carcinoma in cystic fibrosis liver disease: a cautionary tale","volume":"112","author":"O'Brien","year":"2019","journal-title":"QJM"},{"key":"10.1016\/j.jcf.2026.03.022_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100727","article-title":"Hepatocellular carcinoma in cystic fibrosis liver disease","volume":"4","author":"Tarakji","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jcf.2026.03.022_bib0081","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2026.03.022_bib0082","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcf.2025.09.004","article-title":"Real-world pancreatic function recovery and fluctuation in young children with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"24","author":"Schembri","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0084","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2026.03.022_bib0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcf.2025.03.007","article-title":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Wood","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0086","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ncp.11332","article-title":"Evolving nutrition therapy in cystic fibrosis: adapting to the CFTR modulator era","volume":"40","author":"Vavrina","year":"2025","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jcf.2026.03.022_bib0087","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0089","first-page":"54","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"50","author":"Eldredge","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2026.03.022_bib0090","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0091","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","article-title":"Pharmacokinetics of ivacaftor, tezacaftor, elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review","volume":"64","author":"Elzinga","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2026.03.022_bib0092","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0093","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3138\/canlivj-2025-0028","article-title":"Delayed-onset drug-induced liver injury in a cystic fibrosis patient on long-term elexacaftor\/ivacaftor\/tezacaftor therapy: a case report and literature review","volume":"8","author":"Alenezi","year":"2025","journal-title":"Can Liver J"},{"key":"10.1016\/j.jcf.2026.03.022_bib0094","unstructured":"Vertex Orkambi prescribing information. Package Insert. Boston, MA; 2026."},{"key":"10.1016\/j.jcf.2026.03.022_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100752","article-title":"Effect of cystic fibrosis transmembrane conductance regulator modulators on liver enzymes among patients with cystic fibrosis: a systematic review and meta-analysis","volume":"4","author":"Vongsavath","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jcf.2026.03.022_bib0096","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jpn3.70290","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study","volume":"82","author":"Ye","year":"2026","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.022_bib0097","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.02.006","article-title":"Effects of CFTR modulator therapies on liver stiffness and bile flow: a single-centre experience","volume":"79","author":"Calvo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0098","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jcf.2026.03.022_bib0099","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100810","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulating therapies on liver transplant outcomes","volume":"5","author":"Naimimohasses","year":"2026","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jcf.2026.03.022_bib0102","article-title":"Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor","volume":"7","author":"Mouliade","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jcf.2026.03.022_bib0103","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jcf.2025.03.668","article-title":"Resolution of portal hypertension in a patient with cystic fibrosis after treatment with CFTR modulator: a case report","volume":"24","author":"Loon","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(16)30241-2","article-title":"The intestinal microbiome and paediatric liver disease","volume":"2","author":"Leung","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.022_bib0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.jcf.2026.03.022_bib0106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165826","article-title":"Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits","volume":"9","author":"Liang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2026.03.022_bib0107","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2023.03.019","article-title":"Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease","volume":"22","author":"Siegel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2025.02.007","article-title":"Non-invasive evaluation of steatosis and fibrosis in the liver in adults patients living with cystic fibrosis","volume":"24","author":"Pinar-Gutierrez","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.022_bib0109","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4251\/wjgo.v13.i9.1121","article-title":"Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis","volume":"13","author":"Hoskins","year":"2021","journal-title":"World J Gastrointest Oncol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:45:51Z","timestamp":1781883951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199326000901"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.022","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on cystic fibrosis Hepato-biliary involvement","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}